A clinical trial (NCT02296125) evaluating osimertinib demonstrated notable efficacy with reduced adverse effects in NSCLC patients when compared to the conventional EGFR TKIs administered as the primary treatment [15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.